{"id":9847,"date":"2023-10-24T12:41:38","date_gmt":"2023-10-24T10:41:38","guid":{"rendered":"https:\/\/www.geicogroup.com\/becas\/"},"modified":"2025-12-12T12:25:23","modified_gmt":"2025-12-12T11:25:23","slug":"grants","status":"publish","type":"page","link":"https:\/\/www.geicogroup.com\/en\/research\/grants\/","title":{"rendered":"Grants"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Grants<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

At GEICO, we are deeply committed to research and the fight against gynecologic cancer.
Each year, we launch several grant calls aimed at promoting research in this field and improving the health and quality of life of our patients.<\/p>

Our grants are designed to support our researchers and their multidisciplinary teams, who are working on innovative projects to better understand and treat gynecologic cancer.<\/p>

If you are a researcher interested in making a difference in the lives of women affected by gynecologic cancer, we invite you to submit your project for consideration in our annual grant program.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n\n
\n \n
\n \n
\n \n\n\n\n<\/svg> \n <\/div>\n \n
\n GEICO Foundation Grant <\/span>for Research in Gynecologic Tumors 2025\n <\/div>\n \n
<\/div>\n \n
\n APPLICATION CLOSED<\/span>\n <\/div>\n \n <\/div>\n \n
\n \n
\n \n\n\n\n<\/svg> \n <\/div>\n \n
\n GEICO Translational Research Grants<\/span> \u201cAndr\u00e9s Poveda\u201d\n <\/div>\n \n
<\/div>\n \n
\n APPLICATION CLOSED<\/span>\n <\/div>\n \n <\/div>\n \n \n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Grants previously awarded<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n \n
\n \n \n
\n
\n
\n \n
\n 2025 - GEICO Foundation Research Grant in Gynecologic Tumors\n <\/div>\n
\n Constanza Maximiano \/ Alicia Frisuelos\n <\/div>\n \n
\n INCOREPARP: Comprehensive Health and Well-being Plan for Patients with Ovarian Cancer receiving PARP inhibitor treatment. \n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n
\n
\n
\n \n
\n 2025 - GEICO Foundation Research Grant in Gynecologic Tumors\n <\/div>\n
\n GEICO Quality of Life Working Group\n <\/div>\n
\n Prognostic impact of sarcopenia in patients with advanced dMMR\/MSI-H endometrial cancer treated with first-line chemotherapy plus immunotherapy. \n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n
\n
\n
\n \n
\n 2025 - GEICO Translational Research Grant \u201cAndr\u00e9s Poveda\u201d\n <\/div>\n
\n Marta Mendiola \/ Andr\u00e9s Redondo\n <\/div>\n \n
\n ctDNA as a predictive biomarker of benefit from atezolizumab in patients with ovarian cancer treated within the GEICO 69-O \/ ANITA clinical trial. \n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n
\n
\n
\n \n
\n 2025 - GEICO Translational Research Grant \u201cAndr\u00e9s Poveda\u201d \n <\/div>\n
\n Beatriz Tavira \/ Antonio Gonz\u00e1lez\n <\/div>\n
\n Lipidomics and ovarian cancer: study of the role of lipids in the development of resistance to PARP inhibitors and identification of new therapeutic pathways through metabolomics. \n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n\n \n\n
\n
\n
\n \n
\n 2024 - Beca 25 ANIVERSARIO GEICO de investigaci\u00f3n en Tumores Ginecol\u00f3gicos \n <\/div>\n
\n Ana Oaknin \/ Joan Seoane\n <\/div>\n \n
\n Identification of biomarkers to predict response Atezolizumab + Bevacizumab + chemotherapy in metastatic cervical cancer. Analysis of samples from the BEATcc trial \n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n\n \n
\n
\n
\n \n
\n 2024 - GEICO 25th ANNIVERSARY Research Grant in Gynecologic Tumors\n <\/div>\n
\n Ana Oaknin \/ Joan Seoane\n <\/div>\n \n
\n Identification of biomarkers to predict response to Atezolizumab + Bevacizumab + chemotherapy in metastatic cervical cancer. Analysis of samples from the BEATcc trial. \n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n
\n
\n
\n \n
\n 2024 - GEICO 25th ANNIVERSARY Research Grant in Gynecologic Tumors\n <\/div>\n
\n Alejandro Gallego \/ Antonio Gonz\u00e1lez\n <\/div>\n \n
\n Living<\/strong>. Study for the comprehensive evaluation and management of needs and side effects in survivors of advanced gynecologic cancer.<\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n
\n
\n
\n \n
\n 2024 - GEICO Translational Research Grant \u201cAndr\u00e9s Poveda\u201d\n <\/div>\n
\n Rafael Moreno \/ Marta Gil\n <\/div>\n \n
\n Mesenchymal stem cells as a cellular vehicle for an oncolytic adenovirus encoding a bi-specific T-cell activator (BsTE) against FR\u03b1 for the treatment of ovarian cancer.\n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n
\n
\n
\n \n
\n 2024 - GEICO Translational Research Grant \u201cAndr\u00e9s Poveda\u201d\n <\/div>\n
\n Alfonso Cort\u00e9s Salgado\n <\/div>\n \n
\n Antigen expression atlas in a series of endometrial cancer cases molecularly characterized: SPECTRUM Study<\/strong>.\n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n \n
\n
\n
\n \n
\n 2023 - GEICO Translational Research Grant \u201cAndr\u00e9s Poveda\u201d\n <\/div>\n
\n Laura Costas \/ Jordi Ponce\n <\/div>\n \n
\n Mutation analysis of circulating tumor DNA in urine samples for disease monitoring in endometrial cancer.\n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n
\n
\n
\n \n
\n 2023 - GEICO Translational Research Grant \u201cAndr\u00e9s Poveda\u201d\n <\/div>\n
\n Antonio Fern\u00e1ndez \/ Jos\u00e9 Antonio L\u00f3pez - Guerrero\n <\/div>\n \n
\n Predictive study of response to immunotherapy in endometrial cancer based on complete transcriptome analysis (SERENA Study<\/strong>).\n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n
\n
\n \n
\n\n
\n 2022 - GEICO Translational Research Grant \u201cAndr\u00e9s Poveda\u201d\n <\/div>\n
\n Ainhoa Madariaga\n <\/div>\n \n
\n Characterization of immune biomarkers in cervical carcinoma.\n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n
\n
\n \n
\n\n
\n 2022 - GEICO Translational Research Grant \u201cAndr\u00e9s Poveda\u201d\n <\/div>\n
\n Arantzazu Barqu\u00edn\n <\/div>\n \n
\n Prospective observational study for the development of artificial intelligence algorithms capable of predicting the evolution of patients with advanced ovarian cancer by integrating their clinical, pathological, and molecular characteristics.\n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n
\n
\n \n
\n\n
\n 2021 - GEICO Translational Research Grant \u201cAndr\u00e9s Poveda\u201d\n <\/div>\n
\n Alejandro P\u00e9rez - Fidalgo\n <\/div>\n \n
\n Analysis of AXL and its relationship with the immune system as a mechanism of resistance to PARP inhibitors in high-grade ovarian cancer.\n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n\n
\n
\n \n
\n\n
\n 2021 - GEICO Translational Research Grant \u201cAndr\u00e9s Poveda\u201d\n <\/div>\n
\n Jordi Barretina \/ Margarita Romeo\n <\/div>\n \n
\n Resistance to PARP inhibitors in ovarian cancer: identification of biomarkers using Single Cell technology.\n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n
\n
\n \n
\n\n
\n 2020 - GEICO Translational Research Grant \u201cAndr\u00e9s Poveda\u201d\n <\/div>\n
\n Jos\u00e9 Antonio L\u00f3pez - Guerrero\n <\/div>\n \n
\n Predictive model of response to DNA-damaging agents and PARP inhibitors based on genomic scarring (SCARFACE Study<\/strong>).\n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n\n
\n
\n \n
\n\n
\n 2020 - GEICO Translational Research Grant \u201cAndr\u00e9s Poveda\u201d\n <\/div>\n
\n Marta Mendiola \/ Andr\u00e9s Redondo\n <\/div>\n \n
\n Identification of HRD markers and short-term prediction of response to PARP inhibitors in established cell lines and patient-derived organoids in ovarian cancer.\n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n \n
\n
\n \n
\n\n
\n 2020 - GEICO Translational Research Grant \u201cAndr\u00e9s Poveda\u201d\n <\/div>\n
\n Antonio Gonz\u00e1lez \/ Beatriz Tavira\n <\/div>\n \n
\n Identification of markers associated with response to PARP inhibitors and immunotherapy in recurrent ovarian cancer.\n <\/div>\n \n <\/div>\n \n <\/div>\n <\/div>\n\n <\/div>\n\n
\n <\/div>\n\n <\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Grants At GEICO, we are deeply committed to research and the fight against gynecologic cancer.Each year, we launch several grant calls aimed at promoting research in this field and improving the health and quality of life of our patients. Our grants are designed to support our researchers and their multidisciplinary teams, who are working on … Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":9853,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-profesional.php","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-9847","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/comments?post=9847"}],"version-history":[{"count":26,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9847\/revisions"}],"predecessor-version":[{"id":10392,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9847\/revisions\/10392"}],"up":[{"embeddable":true,"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/pages\/9853"}],"wp:attachment":[{"href":"https:\/\/www.geicogroup.com\/en\/wp-json\/wp\/v2\/media?parent=9847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}